纽约州胸主动脉腔内修复术十年:手术量、结局及对腔内技术推广的启示
十年间各组TEVAR植入量均显著增加(P<0.01),近期主动脉夹层使用增加。院内死亡与破裂动脉瘤(OR 5.52)、凝血病(OR 3.38)、脑血管病(OR 2.47)及非白非黑种族(OR 1.74)相关。外科医生或医院手术量均与临床结局无关。
要点
- 十年间各组TEVAR植入量均显著增加(P<0.01),近期主动脉夹层使用增加。
- 院内死亡与破裂动脉瘤(OR 5.52)、凝血病(OR 3.38)和脑血管病(OR 2.47)相关。
- 2011年后多数患者(53%)由低手术量外科医生(每年<3例)完成TEVAR。
核心结论
- 自TEVAR引入以来,不同医院和外科医生手术量分层间获得了可比的结果。
- 即使在低手术量环境中结局也良好,凸显了高难度手术中手术量与结局关系的复杂性。
研究设计与样本
- 查询纽约州全州规划与研究合作系统数据库,识别2005至2014年因主动脉夹层、非破裂动脉瘤和破裂动脉瘤接受TEVAR的患者。
- 评估结局包括院内死亡、并发症和费用,并通过链接国家提供者标识符和纽约职业办公室数据库比较外科医生和医院手术量。
主要发现
- 自引入以来,TEVAR植入在10年期间所有组均显著增加(P<0.01),近期主动脉夹层使用增加。
- 院内死亡增加与破裂动脉瘤(OR 5.52 [3.02-10.08],P<0.01)、凝血病(OR 3.38 [2.02-5.66],P<0.01)、脑血管病(OR 2.47 [1.17-5.22],P=0.02)及非白非黑种族(OR 1.74 [1.08-2.82],P=0.02)相关。
- 在经验早期(2005-2007),患者更可能在高手术量机构(每年>17例)由高手术量外科医生(每年>5例)治疗(P<0.01)。
- 自2011年以来,多数患者(53%)由低手术量外科医生(每年<3例)完成TEVAR。
- 外科医生或医院手术量均与临床结局无关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The purpose of this study was to characterize utilization and outcomes of thoracic endovascular aortic aneurysm repair (TEVAR) in New York State during the first decade of commercial availability, with respect to evolving indications, results, and costs. Of specific interest was evaluation of the volume-outcome relationship for this relatively uncommon procedure. METHODS: The New York Statewide Planning and Research Cooperative System database was queried to identify patients undergoing TEVAR from 2005 to 2014 for aortic dissection (AD), non-ruptured aneurysm (NRA), and ruptured aneurysm (RA). Outcomes assessed included in-hospital mortality, complications, and costs. Linkage to the National Provider Identifier and New York Office of Professions databases facilitated comparisons by surgeon and facility volume. RESULTS: One thousand eight hundred thirty-eight patients were identified: 334 AD, 226 RA, and 1,278 NRA. Since introduction, TEVAR implantation increased significantly over the 10-year period in all groups (P < 0.01), with recent increase in utilization for AD. Increased in-hospital mortality correlated with RA (OR 5.52 [3.02-10.08], P < 0.01), coagulopathy (3.38 [2.02-5.66], P < 0.01), cerebrovascular disease (2.47 [1.17-5.22], P = 0.02), and nonwhite/nonblack race (1.74 [1.08-2.82], P = 0.02). Early in the experience (2005-2007), patients were more likely to be treated at high-volume facilities (>17 per year) and by high-volume surgeons (>5 per year), (P < 0.01). Since 2011, however, most patients (53%) have undergone TEVAR by low-volume surgeons (<3 per year). Neither surgeon nor hospital volume was associated with clinical outcomes. CONCLUSIONS: Since the introduction of TEVAR, comparable results have been obtained across hospital and surgeon volume strata. Favorable outcomes, even in low-volume settings, underscore the complexity of volume-outcome relationships in high-acuity procedures. These findings have implications for credentialing, regionalization, and future dissemination of advanced endovascular technology.
引用
- Stern JR, Sun T, Mao J, et al. A Decade of Thoracic Endovascular Aortic Aneurysm Repair in New York State: Volumes, Outcomes, and Implications for the Dissemination of Endovascular Technology. Ann Vasc Surg. 2018. PMID: 29778610. doi:10.1016/j.avsg.2018.03.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。